---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-013283"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:21:52.560831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen announces positive Phase 2A results for PH15 nasal spray improving psychomotor impairment from mental fatigue

## Summary
- PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.
- Phase 2A pilot study (2011, acquired via Pherin in February 2023) enrolled 10 participants in a crossover design.
- PH15 was safe and well-tolerated; adverse events comparable to placebo, with brief nasal itching in one subject.
- CEO Shawn Singh highlighted potential for shift work disorder, sleep apnea, and narcolepsy patients.
- No serious adverse events reported; caffeine group experienced palpitations, euphoria, dry mouth, stomachache, and polyuria.

## SEC filing metadata
- accession: 0001437749-24-013283
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/0001437749-24-013283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/vtgn20240425_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-013283
- JSON: https://secwatch.observer/filing/0001437749-24-013283.json
- Plain text: https://secwatch.observer/filing/0001437749-24-013283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.